Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia

Thrombosis and Haemostasis

Volumn 112, Issue 1, 2014, Pages 65-72

  Álvarez Román, María Teresa ^a   Fernández Bello, Ihosvany ^a   Arias Salgado, Elena G ^a   Rivas Pollmar, María Isabel ^b   Jiménez Yuste, Víctor ^a,c   Martín Salces, Mónica ^a   Butta, Nora V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Microparticle associated procoagulant state; Platelets; Thrombin generation; Thrombopoietin receptor agonists

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CORTICOSTEROID; ELTROMBOPAG; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN; PHOSPHATIDYLSERINE; PROCOAGULANT; ROMIPLOSTIM; THROMBOPLASTIN; THROMBOPOIETIN RECEPTOR; AUTOANTIBODY; BENZOIC ACID DERIVATIVE; FC RECEPTOR; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN;

ADULT; AGED; AGONIST; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE THROMBOCYTOPENIA; IMMUNOASSAY; MALE; OBSERVATIONAL STUDY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETICULATED PLATELET ASSAY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPOIETIN RECEPTOR AGONIST; VERY ELDERLY; AGONISTS; BLOOD CLOTTING; DRUG EFFECTS; EVALUATION STUDY; IMMUNOLOGY; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PLASMA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOCYTE;

ADULT; AGED; APOPTOSIS; AUTOANTIBODIES; BENZOATES; BLOOD COAGULATION; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; FEMALE; HUMANS; HYDRAZINES; MALE; MIDDLE AGED; PLASMA; PLATELET ACTIVATION; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 84903755610     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-10-0873     Document Type: Article

References (29)

1. Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010; 2010: 377-384.
2. Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol 2011; 153: 437-450.
3. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
4. Panzer S, Hocker L, Rieger M, et al. Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia. Eur J Haematol 2007; 79: 198-204.
5. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
6. Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol 2010; 47: 289-298.
7. Kim KJ, Baek IW, Yoon CH, et al. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013; 161: 706-714.
8. Norgaard M. Thrombosis in patients with primary chronic immune thrombocytopenia. Thromb Res 2012; 130 (Suppl 1): S74-75.
9. Sewify EM, Sayed D, Abdel Aal RF, et al. Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res 2013; 131: e59-63.
10. Schipperus M, Fijnheer R. New therapeutic options for immune thrombocytopenia. Neth J Med 2011; 69: 480-485.
11. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardisation of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393.
12. Hayashi S, Oshida M, Kiyoi T, et al. Reticulated platelet determination: methodologies and applications for the evaluation of thrombocytopenic disorders. Rinsho Ketsueki 1999; 40: 205-212.
13. Hemker HC, Giesen PL, Ramjee M, et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-591.
14. Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 1998; 35: 241-252.
15. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-521.
16. Peng J, Friese P, Wolf RF, et al. Relative reactivity of platelets from thrombopoietin-and interleukin-6-treated dogs. Blood 1996; 87: 4158-4163.
17. Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012; 119: 4066-4072.
18. Martin M, de Paz R, Jimenez-Yuste V, et al. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. Thromb Haemost 2013; 109: 909-919.
19. Ghanima W, Lee SY, Barsam S, et al. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol 2012; 158: 811-814.
20. Dielis AW, Castoldi E, Spronk HM, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-131.
21. Lacroix R, Dignat-George F. Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res 2012; 129 (Suppl 2): S27-29.
22. Bouchard BA, Gissel MT, Whelihan MF, et al. Platelets do not express the oxidized or reduced forms of tissue factor. Biochim Biophys Acta 2013; Epub ahead of print.
23. Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets. Blood 2010; 116: 854-855.
24. Jy W, Johansen ME, Bidot C, Jr., et al. Red cell-derived microparticles (RMP) as haemostatic agent. Thromb Haemost 2013; 110: 751-760.
25. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663-1674.
26. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363: 1889-1899.
27. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95: 1167-1175.
28. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171.
29. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.